Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...

The most common reason for delaying or not receiving care was not getting an appointment when they needed one, cited by 39% of respondents. More than half (56%) of patients reported delays in ...

Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due ...

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

The Levy family is excited to be recognized as the 2025 New England Take Steps Honored Family, and Soliel as the Honored Hero ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

Older adults with moderate to severe IBD can achieve remission with JAK inhibitors, according to a study presented at Crohn’s & Colitis Congress.

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

Patient activation, earned trust and health literacy at patient, provider and health system levels are critical to overcoming ...